Ameritas Investment Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Ameritas Investment Partners’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-867	Closed	-$4.54K	–	3267
2024 Q1	$4.54K	Hold	867	–	–	﹤0.01%	2961
2023 Q4	$4.53K	Hold	867	–	–	﹤0.01%	2984
2023 Q3	$13.7K	Hold	867	–	–	﹤0.01%	2701
2023 Q2	$16.9K	Hold	867	–	–	﹤0.01%	2646
2023 Q1	$24.6K	Hold	867	–	–	﹤0.01%	2385
2022 Q4	$29.2K	Hold	867	–	–	﹤0.01%	2380
2022 Q3	$22K	Hold	867	–	–	﹤0.01%	2492
2022 Q2	$38K	Hold	867	–	–	﹤0.01%	2176
2022 Q1	$43K	Hold	867	–	–	﹤0.01%	2148
2021 Q4	$44K	Hold	867	–	–	﹤0.01%	2206
2021 Q3	$48K	Hold	867	–	–	﹤0.01%	2189
2021 Q2	$37K	Hold	867	–	–	﹤0.01%	2391
2021 Q1	$36K	Hold	867	–	–	﹤0.01%	2282
2020 Q4	$40K	Hold	867	–	–	﹤0.01%	2116
2020 Q3	$37K	Hold	867	–	–	﹤0.01%	2030
2020 Q2	$42K	Hold	867	–	–	﹤0.01%	1943
2020 Q1	$40K	Hold	867	–	–	﹤0.01%	1792
2019 Q4	$52K	Hold	867	–	–	﹤0.01%	1900
2019 Q3	$49K	Hold	867	–	–	﹤0.01%	1890
2019 Q2	$48K	Hold	867	–	–	﹤0.01%	1939
2019 Q1	$44K	Hold	867	–	–	﹤0.01%	1960
2018 Q4	$35K	Hold	867	–	–	﹤0.01%	2019
2018 Q3	$60K	Hold	867	–	–	﹤0.01%	1890
2018 Q2	$66K	Buy	867 +120	+16%	+$7.55K	﹤0.01%	1818
2018 Q1	$39K	Hold	747	–	–	﹤0.01%	2058
2017 Q4	$40K	Hold	747	–	–	﹤0.01%	2052
2017 Q3	$40K	Hold	747	–	–	﹤0.01%	2030
2017 Q2	$59K	Buy	747 +85	+13%	+$6.95K	﹤0.01%	1799
2017 Q1	$55K	Buy	+662	New	+$49.2K	﹤0.01%	1781

Other funds holding EGRX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameritas Investment Partners's EGRX Position: Q2 2024 in Review

Ameritas Investment Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 867 shares — an estimated $4.54K sold.

Ameritas Investment Partners first reported a position in EGRX in Q1 2017 and held it in 29 quarters. The position peaked at $66K in Q2 2018. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

Ameritas Investment Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
Ameritas Investment Partners sold 867 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $4.54K.
Ameritas Investment Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2017 and held it in 29 quarters.
Ameritas Investment Partners's Eagle Pharmaceuticals, Inc. position peaked at $66K in Q2 2018.
75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Ameritas Investment Partners's 13F filing for Q2 2024, filed 13 Aug 2024.